22 material Form 8-K filings that 21 companies we cover made with the SEC in August 2023, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Berkshire Hathaway reported second-quarter 2023 net earnings attributable to shareholders of $35.9 billion, compared with a net loss of $43.6 billion in the second quarter of 2022. Operating earnings, which exclude investment and derivative gains and losses, rose to $10.0 billion from $9.4 billion, and the company said it repurchased about $1.4 billion of its shares during the quarter.
Net earnings were $35.9 billion in Q2 2023 versus a $43.6 billion loss in Q2 2022; investment and derivative gains were $25.9 billion, compared with losses of $53.0 billion a year earlier.
Operating earnings were $10.0 billion in Q2 2023, up from $9.4 billion in Q2 2022.
Berkshire repurchased about $1.4 billion of its shares in Q2 2023, bringing the six-month total to $5.8 billion.
Insurance float was about $166 billion at June 30, 2023, up about $2 billion from year-end 2022.
Krystal Biotech reported a second-quarter 2023 net loss of $33.2 million, or $(1.25) per share, up from $28.1 million, or $(1.10) per share, a year earlier. The filing reports no revenue figure; it cites 121 Patient Start Forms for VYJUVEK in the first six weeks after its May 19 FDA approval, and $505.9 million in cash, cash equivalents and investments at June 30, 2023.
Q2 2023 net loss was $33.2 million, or $(1.25) per share, versus $28.1 million, or $(1.10) per share, in Q2 2022.
General and administrative expenses rose to $25.9 million from $17.9 million, and R&D expenses rose to $12.1 million from $10.9 million.
As of June 30, the company had received 121 VYJUVEK Patient Start Forms, 30 of them for dominant dystrophic epidermolysis bullosa.
Cash, cash equivalents and investments totaled $505.9 million on June 30, 2023.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.